Evidence map›Paper›PMID 38222052›Full record

ReviewNeuro-oncology practice2024

Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019.

Mackenzie Price, Katherine Ryan, Madison L Shoaf, Corey Neff, J Bryan Iorgulescu, Daniel B Landi, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S Barnholtz-Sloan and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Dabrafenib in pediatric patients withNeuro-oncology practice · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mackenzie PriceDepartment of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0001-6369-0609
Katherine RyanDepartment of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
Madison L ShoafDepartment of Neurology, Emory University, Atlanta, GA, USA.
Corey NeffDepartment of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0001-9479-2747
J Bryan IorgulescuMolecular Diagnostics Laboratory, Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-1405-3667
Daniel B LandiDepartment of Pediatrics, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0002-1487-1136
Gino CioffiCentral Brain Tumor Registry of the United States, Hinsdale, IL, USA.ORCID https://orcid.org/0000-0002-3296-8652
Kristin A WaiteCentral Brain Tumor Registry of the United States, Hinsdale, IL, USA.ORCID https://orcid.org/0000-0002-3186-8510
Carol KruchkoCentral Brain Tumor Registry of the United States, Hinsdale, IL, USA.ORCID https://orcid.org/0000-0001-7212-035X
Jill S Barnholtz-SloanCentral Brain Tumor Registry of the United States, Hinsdale, IL, USA.ORCID https://orcid.org/0000-0001-6190-9304
Quinn T OstromDepartment of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0003-3469-7558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-based data for primary brain and other central nervous system (CNS) in the US. CBTRUS publishes an annual statistical report which provides critical reference data for the broad neuro-oncology community. Here, we summarize the key findings from the 2022 CBTRUS annual statistical report for healthcare providers. Methods: Incidence data were obtained from the CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results Program for 52 central cancer registries (CCRs). Survival data were obtained from 42 NPCR CCRs. All rates are per 100 000 and age-adjusted using the 2000 US standard population. Overall median survival was estimated using Kaplan-Meier models. Survival data for selected molecularly defined histopathologies are from the National Cancer Database. Mortality data are from the National Vital Statistics System. Results: The average annual age-adjusted incidence rate of all primary brain and other CNS tumors was 24.25/100 000. Incidence was higher in females and non-Hispanics. The most commonly occurring malignant and predominately non-malignant tumors was glioblastoma (14% of all primary brain tumors) and meningioma (39% of all primary brain tumors), respectively. Mortality rates and overall median survival varied by age, sex, and histopathology. Conclusions: This summary describes the most up-to-date population-based incidence, mortality, and survival, of primary brain and other CNS tumors in the US and aims to serve as a concise resource for neuro-oncology providers.

Indexed as

brain tumorsCentral Brain Tumor Registry of the United Statesepidemiologyneuro-oncology

Identifiers

PMID38222052
PMCPMC10785588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.